4.99
price up icon1.84%   0.09
after-market 시간 외 거래: 4.99
loading
전일 마감가:
$4.90
열려 있는:
$5.01
하루 거래량:
1,952
Relative Volume:
0.05
시가총액:
$4.56M
수익:
$61,000
순이익/손실:
$-5.46M
주가수익비율:
-0.763
EPS:
-6.54
순현금흐름:
$-6.76M
1주 성능:
+1.22%
1개월 성능:
+4.46%
6개월 성능:
+35.97%
1년 성능:
-37.62%
1일 변동 폭
Value
$4.89
$5.01
1주일 범위
Value
$4.31
$5.335
52주 변동 폭
Value
$3.03
$8.44

타이탄 파마슈티컬스 Stock (TTNP) Company Profile

Name
명칭
Titan Pharmaceuticals Inc De
Name
전화
(650) 244-4990
Name
주소
400 OYSTER POINT BLVD, SAN FRANCISCO
Name
직원
4
Name
트위터
@titanpharma
Name
다음 수익 날짜
2024-06-28
Name
최신 SEC 제출 서류
Name
TTNP's Discussions on Twitter

TTNP을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
TTNP
Titan Pharmaceuticals Inc De
4.99 6.89M 61,000 -5.46M -6.76M -6.54
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
395.12 99.96B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
589.48 60.83B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
454.38 59.89B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
660.00 40.47B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
313.67 37.96B 3.81B -644.79M -669.77M -6.24

타이탄 파마슈티컬스 Stock (TTNP) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2019-06-26 개시 Maxim Group Buy
2017-11-10 다운그레이드 ROTH Capital Buy → Neutral

타이탄 파마슈티컬스 주식(TTNP)의 최신 뉴스

pulisher
Aug 20, 2025

Will a bounce in CEMEX S.A.B. de C.V. Depositary Receipt offer an exitJuly 2025 Analyst Calls & High Accuracy Swing Entry Alerts - Newser

Aug 20, 2025
pulisher
Aug 16, 2025

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) Short Interest Up 304.7% in July - Defense World

Aug 16, 2025
pulisher
Aug 14, 2025

Elite Pharmaceuticals Revenue More Than Doubles as New ADHD Drug Launch Drives Record Growth - Stock Titan

Aug 14, 2025
pulisher
Aug 14, 2025

How Titan Pharmaceuticals Inc. stock performs during market volatilityMarket Growth Summary & Expert Curated Trade Ideas - Newser

Aug 14, 2025
pulisher
Aug 13, 2025

Sonoma's First Major Consumer Product Hits Walmart Shelves: New Tech-Based Diaper Rash Treatment - Stock Titan

Aug 13, 2025
pulisher
Aug 12, 2025

Ketamir-2 outperforms ketamine, plans Phase 2a FDA submission in Q4 2025 - Stock Titan

Aug 12, 2025
pulisher
Aug 11, 2025

CVKD Files 8-K; Exhibit 99.1 Contains Q2 2025 Financials - Stock Titan

Aug 11, 2025
pulisher
Aug 10, 2025

Will earnings trigger a reversal in Titan Pharmaceuticals Inc.Daily Swing Candidate Analysis with Chart Patterns - Newser

Aug 10, 2025
pulisher
Aug 09, 2025

Best Pharmaceutical Stocks to Buy in 2025 - The Motley Fool

Aug 09, 2025
pulisher
Aug 08, 2025

Elite Pharmaceuticals Earnings Call: Key Corporate Updates and Q1 2026 Results Coming August 15 - Stock Titan

Aug 08, 2025
pulisher
Aug 08, 2025

NRx Secures Florida Approval to Acquire Veterans Mental Health Provider Dura Medical - Stock Titan

Aug 08, 2025
pulisher
Aug 08, 2025

Kiora's Q2 Earnings Reveal Dual Phase 2 Trials Progress and $110M Asia Partnership Opportunity - Stock Titan

Aug 08, 2025
pulisher
Aug 07, 2025

PLBY regains Nasdaq compliance with new independent director appointment | PCSA SEC FilingForm 8-K - Stock Titan

Aug 07, 2025
pulisher
Aug 06, 2025

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates - GlobeNewswire

Aug 06, 2025
pulisher
Aug 06, 2025

RIGL files S-8 to register 825,000 shares for employee equity plans | RIGL SEC FilingForm S-8 - Stock Titan

Aug 06, 2025
pulisher
Aug 05, 2025

TITAN PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Titan Pharmaceuticals, Inc.TTNP - FinancialContent

Aug 05, 2025
pulisher
Aug 05, 2025

Cumberland Pharmaceuticals Hits 23% Revenue Growth as DMD Drug Shows Major Heart Benefits - Stock Titan

Aug 05, 2025
pulisher
Aug 05, 2025

Nuvectis Reports Clinical Trial Success: NXP900 Cancer Drug Advances as Cash Position Strengthens to $39M - Stock Titan

Aug 05, 2025
pulisher
Aug 04, 2025

Biotech Terns Pharmaceuticals Appoints Chief People Officer, Awards Massive 500,000 Share Option Package - Stock Titan

Aug 04, 2025
pulisher
Aug 04, 2025

Ex-Takeda Rare Disease Chief Joins Catalyst Pharmaceuticals Board to Drive Strategic Growth - Stock Titan

Aug 04, 2025
pulisher
Aug 01, 2025

Xenon Pharmaceuticals Expands Team: Grants $739K in Stock Options to 6 New Hires - Stock Titan

Aug 01, 2025
pulisher
Jul 31, 2025

SHEN files 8-K, releases Q2 2025 earnings press release | ADIL SEC FilingForm 424B5 - Stock Titan

Jul 31, 2025
pulisher
Jul 31, 2025

Acurx Pharmaceuticals Plans Major 1:20 Reverse SplitKey Details for Nasdaq Compliance - Stock Titan

Jul 31, 2025
pulisher
Jul 31, 2025

Lexicon Pharmaceuticals Meets $1 Minimum Share Price, Secures Critical Nasdaq Listing Status - Stock Titan

Jul 31, 2025
pulisher
Jul 29, 2025

Cumberland Pharmaceuticals Sets Q2 Earnings Date: FDA-Approved Drug Portfolio Update Coming August 5 - Stock Titan

Jul 29, 2025
pulisher
Jul 29, 2025

NRx Pharmaceuticals Teams with Yale Expert to Reveal Latest CNS Treatment Innovations at BTIG Conference - Stock Titan

Jul 29, 2025
pulisher
Jul 29, 2025

MIRA's Novel Pain Drug Shows 112% Better Relief Than Current Treatments, FDA Gives Green Light - Stock Titan

Jul 29, 2025
pulisher
Jul 28, 2025

INM files 8-K on upcoming INM-901 Alzheimer’s data at AAIC 2025 | INM SEC FilingForm 8-K - Stock Titan

Jul 28, 2025
pulisher
Jul 28, 2025

Supernus-Sage $12B Merger Gets Key Regulatory Green Light as Tender Offer Deadline Nears - Stock Titan

Jul 28, 2025
pulisher
Jul 27, 2025

What are the latest earnings results for Titan Pharmaceuticals Inc.Achieve explosive financial results today - Jammu Links News

Jul 27, 2025
pulisher
Jul 26, 2025

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CARM, ENZB, HSON, TTNP on Behalf of Shareholders - GlobeNewswire Inc.

Jul 26, 2025
pulisher
Jul 25, 2025

Phio Pharmaceuticals Advances Cancer Drug Production with Strategic US Manufacturing Partnership - Stock Titan

Jul 25, 2025
pulisher
Jul 24, 2025

Apellis Pharmaceuticals Q2 Earnings: Complement Medicine Pioneer Reports Latest Financial Performance - Stock Titan

Jul 24, 2025
pulisher
Jul 23, 2025

Lexicon Pharmaceuticals Schedules Pre-Market Q2 Earnings Release, 8:30 AM ET Conference Call - Stock Titan

Jul 23, 2025
pulisher
Jul 22, 2025

CNS Pharmaceuticals CEO Shares Brain Cancer Treatment Vision at Investor Conference | CNSP Stock News - Stock Titan

Jul 22, 2025
pulisher
Jul 21, 2025

Amneal (AMRX) targets $2.55B debt refinancing via loans & notes | AMRX SEC FilingForm 8-K - Stock Titan

Jul 21, 2025
pulisher
Jul 18, 2025

MEI Pharma Announces $100,000,000 Private Placement to Initiate Litecoin Treasury Strategy, Becoming First and Only Publicly Traded LTC Holder on a National Exchange - Business Wire

Jul 18, 2025
pulisher
Jul 18, 2025

What analysts say about Titan Pharmaceuticals Inc. stockFree Smart Trading Workshop - jammulinksnews.com

Jul 18, 2025
pulisher
Jul 18, 2025

HOOKIPA Pharma Exits Nasdaq Market as Gilead Sciences Acquires Key Drug Programs - Stock Titan

Jul 18, 2025
pulisher
Jul 16, 2025

60 Degrees Pharmaceuticals Announces Closing of up to $10 Million Public Offering - Stock Titan

Jul 16, 2025
pulisher
Jul 15, 2025

Rani Therapeutics Secures $3M Financing Deal: Biotech Firm Prices Shares at $0.40 in Strategic Offering - Stock Titan

Jul 15, 2025
pulisher
Jul 15, 2025

Major FDA Development: Pierre Fabre Assumes Control of Atara's EBV Cell Therapy Program After BLA Resubmission - Stock Titan

Jul 15, 2025
pulisher
Jul 15, 2025

INKT sets up $50M ATM with B. Riley, adds financing flexibility | INKT SEC FilingForm 8-K - Stock Titan

Jul 15, 2025
pulisher
Jul 14, 2025

ESSA Pharma Shareholders to Receive $1.91 Cash Plus CVR in XenoTherapeutics Acquisition Deal - Stock Titan

Jul 14, 2025
pulisher
Jul 11, 2025

RYTM raises $188.7M via 2.37M-share offering at $85 | RYTM SEC FilingForm 8-K - Stock Titan

Jul 11, 2025
pulisher
Jul 11, 2025

MIST gets FDA review nod; PDUFA set for Dec 13 2025 – covenant aligned | MIST SEC FilingForm 8-K - Stock Titan

Jul 11, 2025
pulisher
Jul 11, 2025

FDA Sets New December 2025 Decision Date for Milestone's PSVT Nasal Spray, Secures $75M Funding - Stock Titan

Jul 11, 2025
pulisher
Jul 10, 2025

Local Bounti (LOCL) insider files Form 144 to sell 3,500 shares - Stock Titan

Jul 10, 2025
pulisher
Jul 10, 2025

Rhythm Pharmaceuticals Raises Massive $175M in Upsized Offering for Rare Disease Drug Development - Stock Titan

Jul 10, 2025
pulisher
Jul 09, 2025

GILT lands >$22M Tier-One satellite orders, boosts multi-orbit momentum | EVOK SEC FilingForm 8-K - Stock Titan

Jul 09, 2025
pulisher
Jul 08, 2025

Citius Pharma Dodges Delisting: Stock Maintains $1+ Price for 10 Straight Days, Secures Nasdaq Future - Stock Titan

Jul 08, 2025

타이탄 파마슈티컬스 (TTNP) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$24.65
price up icon 0.94%
$85.04
price down icon 1.72%
$26.20
price up icon 0.73%
$110.88
price up icon 0.10%
$131.88
price down icon 0.54%
biotechnology ONC
$313.67
price down icon 0.10%
자본화:     |  볼륨(24시간):